Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).

Inclusion Criteria:

• Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease
• Measurable disease
• Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry

Exclusion Criteria:

• Prior chemotherapy for metastatic disease
• HER2 positive and/or hormonal receptor positive